At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 449 enrolled
Drug / intervention
Desloratadine 5 mg +1 moredrug
Likely dose
Desloratadine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Desloratadine 5 mg and Placebo for Seasonal Allergic Rhinitis. Completed, enrolled 449 participants.
Detailed Summary
This is an efficacy and safety study of desloratadine (MK-4117) in Japanese participants with seasonal allergic rhinitis (SAR). The primary hypothesis of this study is that the change from Baseline in Total Nasal Symptom Score (TNSS) is improved by desloratadine compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionApr 2015
TodayJul 2026
First PostedDec 19, 2014
Enrollment StartJan 9, 2015
Primary CompletionApr 27, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.5 years ago
Interventions
Desloratadine 5 mgdrug
Desloratadine 5 mg tablets
Placebodrug
Placebo tablets